Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director | June 04, 2024 | June 06, 2024 |
| PDS Biotechnology CorpPDSB · Entity 7939 | Director | January 12, 2026 | March 03, 2026 |
| ZyVersa Therapeutics, Inc.ZVSA · Entity 8639 | Director | July 11, 2025 | July 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date June 04, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 283,498 |
Reported balance
After 2024-06-04 transaction · row 1
1 source rowRow 1 · 2024-06-04 · Exercise / conversion · Acquired 11,904 · Balance 283,498 F1: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Exercise / conversion · Disposed 11,904 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock.
F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
PDS Biotechnology Corp
Report date January 12, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-01-12 | Direct | 54,876 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 54,876 · Balance 54,876 F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
ZyVersa Therapeutics, Inc.
Report date July 11, 2025 · Filed July 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2035-07-11 | Direct | 11,066 |
Reported balance
After 2025-07-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-11 · Grant · Acquired 11,066 · Balance 11,066 F1: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Mar 3, 2026 18:47 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 54,876 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001140361-26-007643 · form4.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,876 Underlying: Common Stock · 54,876 shares Expires 2036-01-12 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 16:22 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options · Derivative | 11,066 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001641172-25-019724 · ownership.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,066 Underlying: Common Stock · 11,066 shares Expires 2035-07-11 F1 · derivative.exercise_date: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 18:00 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,700 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001140361-25-022224 · form4.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,700 Underlying: Common Stock · 22,700 shares Expires 2035-06-11 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 16:45 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Warrant · Derivative | 15,060 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001140361-25-006784 · form4.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,060 Underlying: Common Stock · 15,060 shares Expires 2030-02-28 F1 · price: The purchase price for the Common Warrant is included in the purchase price for the shares of Common Stock reflected in Table I above. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 16:45 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Stock | 15,060 | $1.66 | $24,999.60 |
DisclosureSEC source: 0001140361-25-006784 · form4.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,213 Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 16:05 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001140361-24-031294 · form4.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:49 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000075 · wk-form4_1717706957.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock. F1 · derivative.expiration_date: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:49 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000075 · wk-form4_1717706957.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:31 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 25,000 | $9.00 | $225,000.00 |
DisclosureSEC source: 0000805928-24-000039 · wk-form4_1709937069.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,594 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.95 to $9.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:28 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000112 · wf-form4_169408247926456.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:28 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-23-000112 · wf-form4_169408247926456.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 17:30 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001140361-23-034839 · form4.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2033-07-14 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:47 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000062 · wf-form4_168600524446062.xml · derivative · entry 4 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. F5 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:47 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000062 · wf-form4_168600524446062.xml · nonDerivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: This reflects the number of restricted stock units that vested on June 1, 2023. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:47 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 29,480 | $8.74 | $257,655.20 |
DisclosureSEC source: 0000805928-23-000062 · wf-form4_168600524446062.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,135 F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:47 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 12,500 | $8.65 | $108,125.00 |
DisclosureSEC source: 0000805928-23-000062 · wf-form4_168600524446062.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,615 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.57 to $8.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 24, 2023 Filed Jul 18, 2024 21:35 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options · Derivative | 132 | $0.00 Strike: $152.46 | $0.00 |
DisclosureSEC source: 0001493152-24-028399 · ownership.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132 Underlying: Common Stock · 132 shares Expires 2033-05-24 F1 · date: The option disclosed on this Form 4 was not previously reported due to an administrative oversight. F2 · shares: Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024. F3 · derivative.exercise_date: The option vests annually in three equal installments commencing on May 24, 2024. Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 4,640 | $9.26 | $42,966.40 |
DisclosureSEC source: 0000805928-23-000056 · wf-form4_168495914913321.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,115 F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.21 to $9.54 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 2,828 | $9.17 | $25,932.76 |
DisclosureSEC source: 0000805928-23-000056 · wf-form4_168495914913321.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,755 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.15 to $9.20 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:05 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 13,000 | $12.74 | $165,620.00 |
DisclosureSEC source: 0000805928-22-000121 · wf-form4_166863270834343.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,583 F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · acquired: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.51 to $13.07 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 13,000 | $12.50 | $162,500.00 |
DisclosureSEC source: 0000805928-22-000119 · wf-form4_166811453210822.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,583 F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 01:50 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 8,886 | $9.70 | $86,158.66 |
DisclosureSEC source: 0000805928-22-000107 · wf-form4_166026898857805.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,583 F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · acquired: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.50 to $9.99 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2022 Filed Aug 8, 2022 21:49 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 13,046 | $10.37 | $135,287.02 |
DisclosureSEC source: 0000805928-22-000105 · wf-form4_165999536701295.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,469 F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F3 · acquired: The reported price in Colum 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging for $10.15 to $10.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote, Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 21:49 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 24,000 | $10.64 | $255,360.00 |
DisclosureSEC source: 0000805928-22-000105 · wf-form4_165999536701295.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,515 F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · acquired: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.35 to $10.88 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 00:42 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 83,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0000805928-22-000098 · wf-form4_165888256034498.xml · derivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,000 shares Expires 2022-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 00:42 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 30,296 | $9.26 | $280,540.96 |
DisclosureSEC source: 0000805928-22-000098 · wf-form4_165888256034498.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,515 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 83,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 52,704 shares of common stock. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 00:42 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 83,000 | $3.38 | $280,540.00 |
DisclosureSEC source: 0000805928-22-000098 · wf-form4_165888256034498.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 83,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 52,704 shares of common stock. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 16:15 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001140361-22-024465 · form4.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000062 · wf-form4_165428677346545.xml · derivative · entry 4 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 Underlying: Common Stock · 6,459 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 11,811 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0000805928-22-000062 · wf-form4_165428677346545.xml · derivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,811 Underlying: Common Stock · 11,811 shares Expires 2032-06-01 F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000062 · wf-form4_165428677346545.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,036 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000062 · wf-form4_165428677346545.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 18:45 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001140361-21-021489 · form4.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-06-17 F2 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on June 17, 2022. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 9,250 | $0.00 Strike: $19.17 | $0.00 |
DisclosureSEC source: 0000805928-21-000121 · wf-form4_162430665353712.xml · derivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,250 shares Expires 2028-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 8,781 | $20.92 | $183,698.52 |
DisclosureSEC source: 0000805928-21-000121 · wf-form4_162430665353712.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,775 F1 · shares: Of the 8,781 reported shares, 8,477 shares were swapped to cover the exercise price of the options exercised via an attestation method stock swap in accordance with Rule 16b-3. Additionally, 304 shares of common stock were surrendered to satisfy the reporting person's tax withholding liability. In total, the reporting person received 469 additional shares of common stock. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 9,250 | $19.17 | $177,322.50 |
DisclosureSEC source: 0000805928-21-000121 · wf-form4_162430665353712.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Of the 8,781 reported shares, 8,477 shares were swapped to cover the exercise price of the options exercised via an attestation method stock swap in accordance with Rule 16b-3. Additionally, 304 shares of common stock were surrendered to satisfy the reporting person's tax withholding liability. In total, the reporting person received 469 additional shares of common stock. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 18:45 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Stock | 5,882 | $8.50 | $49,997.00 |
DisclosureSEC source: 0001140361-21-021489 · form4.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,153 F1 · kind: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on June 17, 2021, and such shares of common stock are subject to a lock up agreement between the Reporting Person and Cantor Fitzgerald & Co., pursuant to which the shares cannot be sold for 90 days following June 15, 2021. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 24,000 | $3.67 Strike: $3.67 | $88,080.00 |
DisclosureSEC source: 0000805928-21-000118 · wf-form4_162318390357941.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares pursuant to the employee stock option will became vested on December 29, 2018 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vested on December 29, 2015 (12 months from the option grant date) and an additional 12.5% of the aggregate shares each 6 months thereafter. F1 · derivative.expiration_date: All shares pursuant to the employee stock option will became vested on December 29, 2018 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vested on December 29, 2015 (12 months from the option grant date) and an additional 12.5% of the aggregate shares each 6 months thereafter. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 24,000 | $3.67 | $88,080.00 |
DisclosureSEC source: 0000805928-21-000118 · wf-form4_162318390357941.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000110 · wf-form4_162275480526647.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,036 Underlying: Common Stock · 3,036 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 6,030 | $0.00 Strike: $19.76 | $0.00 |
DisclosureSEC source: 0000805928-21-000110 · wf-form4_162275480526647.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires 2031-06-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 50,000 | $8.95 Strike: $8.95 | $447,500.00 |
DisclosureSEC source: 0000805928-21-000099 · wf-form4_162223233198745.xml · derivative · entry 10 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 29, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vested on December 29, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vested each 6 months thereafter. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 15,000 | $5.45 Strike: $5.45 | $81,750.00 |
DisclosureSEC source: 0000805928-21-000099 · wf-form4_162223233198745.xml · derivative · entry 9 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 31, 2016. The option vested in two equal installments beginning on September 30, 2016, and became fully vested on December 31, 2016. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 6,000 | $5.45 Strike: $5.45 | $32,700.00 |
DisclosureSEC source: 0000805928-21-000099 · wf-form4_162223233198745.xml · derivative · entry 8 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2023-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on May 26, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vested on May 26, 2017(12 months from the option grant date) and an additional 12.5% of the aggregate shares vested each 6 months thereafter. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 9,000 | $5.09 Strike: $5.09 | $45,810.00 |
DisclosureSEC source: 0000805928-21-000099 · wf-form4_162223233198745.xml · derivative · entry 7 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2022-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 29, 2019 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vested on December 29, 2016 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vested each 6 months thereafter. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 22,954 | $3.67 Strike: $3.67 | $84,241.18 |
DisclosureSEC source: 0000805928-21-000099 · wf-form4_162223233198745.xml · derivative · entry 6 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,954 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 29, 2018 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vested on December 29, 2015 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vested each 6 months thereafter. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 50,000 | $8.95 | $447,500.00 |
DisclosureSEC source: 0000805928-21-000099 · wf-form4_162223233198745.xml · nonDerivative · entry 5 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 15,000 | $5.45 | $81,750.00 |
DisclosureSEC source: 0000805928-21-000099 · wf-form4_162223233198745.xml · nonDerivative · entry 4 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,000 | $5.45 | $32,700.00 |
DisclosureSEC source: 0000805928-21-000099 · wf-form4_162223233198745.xml · nonDerivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 9,000 | $5.09 | $45,810.00 |
DisclosureSEC source: 0000805928-21-000099 · wf-form4_162223233198745.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.